Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company's stock, valued at $70,873,516.56. The sale was disclosed in a document filed with the SEC, which is available through this link.
Thermo Fisher Scientific Stock Up 1.1 %
NYSE:TMO opened at $575.11 on Thursday. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a market cap of $219.53 billion, a price-to-earnings ratio of 36.89, a price-to-earnings-growth ratio of 2.36 and a beta of 0.80. The stock has a fifty day simple moving average of $575.03 and a 200-day simple moving average of $531.97. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current year.
Thermo Fisher Scientific Increases Dividend
[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks
From Crypto 101 Media | Ad
Are you monitoring 13,217 cryptocurrencies everyday?
If not, you could miss the ONE that can make you wealthy beyond your wildest dreams.
You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls.
Claim your free seat by clicking here now.
The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific's payout ratio is presently 10.01%.
Institutional Trading of Thermo Fisher Scientific
Several institutional investors and hedge funds have recently made changes to their positions in the company. Moloney Securities Asset Management LLC raised its holdings in shares of Thermo Fisher Scientific by 1.4% in the first quarter. Moloney Securities Asset Management LLC now owns 2,410 shares of the medical research company's stock valued at $1,401,000 after acquiring an additional 33 shares in the last quarter. Rockline Wealth Management LLC raised its holdings in shares of Thermo Fisher Scientific by 9.1% in the first quarter. Rockline Wealth Management LLC now owns 1,299 shares of the medical research company's stock valued at $755,000 after acquiring an additional 108 shares in the last quarter. Main Street Research LLC grew its stake in Thermo Fisher Scientific by 12.9% in the first quarter. Main Street Research LLC now owns 1,605 shares of the medical research company's stock valued at $934,000 after purchasing an additional 183 shares during the last quarter. Valley Brook Capital Group Inc. grew its stake in Thermo Fisher Scientific by 2.1% in the first quarter. Valley Brook Capital Group Inc. now owns 4,760 shares of the medical research company's stock valued at $2,767,000 after purchasing an additional 100 shares during the last quarter. Finally, Palisade Asset Management LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at about $53,000. 89.23% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on TMO shares. Royal Bank of Canada increased their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an "outperform" rating in a report on Thursday, February 1st. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a "neutral" rating and a $620.00 price objective for the company. Raymond James raised their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an "outperform" rating in a report on Thursday, February 1st. Evercore ISI raised their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an "outperform" rating in a report on Thursday, April 4th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a "buy" rating in a report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $607.35.
Read Our Latest Report on TMO
Thermo Fisher Scientific Company Profile
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
